289 related articles for article (PubMed ID: 26269118)
1. Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles.
Tang E; Ravaud P; Riveros C; Perrodeau E; Dechartres A
BMC Med; 2015 Aug; 13():189. PubMed ID: 26269118
[TBL] [Abstract][Full Text] [Related]
2. Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals.
Riveros C; Dechartres A; Perrodeau E; Haneef R; Boutron I; Ravaud P
PLoS Med; 2013 Dec; 10(12):e1001566; discussion e1001566. PubMed ID: 24311990
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Data on Serious Adverse Events and Mortality in ClinicalTrials.gov, Corresponding Journal Articles, and FDA Medical Reviews: Cross-Sectional Analysis.
Pradhan R; Singh S
Drug Saf; 2018 Sep; 41(9):849-857. PubMed ID: 29644579
[TBL] [Abstract][Full Text] [Related]
4. Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications.
Hartung DM; Zarin DA; Guise JM; McDonagh M; Paynter R; Helfand M
Ann Intern Med; 2014 Apr; 160(7):477-83. PubMed ID: 24687070
[TBL] [Abstract][Full Text] [Related]
5. Selective reporting bias in randomised controlled trials from two network meta-analyses: comparison of clinical trial registrations and their respective publications.
Wong EK; Lachance CC; Page MJ; Watt J; Veroniki A; Straus SE; Tricco AC
BMJ Open; 2019 Sep; 9(9):e031138. PubMed ID: 31492792
[TBL] [Abstract][Full Text] [Related]
6. Public availability of results of observational studies evaluating an intervention registered at ClinicalTrials.gov.
Baudart M; Ravaud P; Baron G; Dechartres A; Haneef R; Boutron I
BMC Med; 2016 Jan; 14():7. PubMed ID: 26819213
[TBL] [Abstract][Full Text] [Related]
7. Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study.
Hughes S; Cohen D; Jaggi R
BMJ Open; 2014 Jul; 4(7):e005535. PubMed ID: 25009136
[TBL] [Abstract][Full Text] [Related]
8. Do Published Data in Trials Assessing Cancer Drugs Reflect the Real Picture of Efficacy and Safety?
Lv JW; Chen YP; Zhou GQ; Liu X; Guo Y; Mao YP; Ma J; Sun Y
J Natl Compr Canc Netw; 2017 Nov; 15(11):1363-1371. PubMed ID: 29118228
[No Abstract] [Full Text] [Related]
9. The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors.
Karimian Z; Mavoungou S; Salem JE; Tubach F; Dechartres A
BMC Cancer; 2020 Nov; 20(1):1128. PubMed ID: 33225901
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials on drug-drug interactions registered in ClinicalTrials.gov reported incongruent safety data in published articles: an observational study.
Jurić D; Pranić S; Tokalić R; Milat AM; Mudnić I; Pavličević I; Marušić A
J Clin Epidemiol; 2018 Dec; 104():35-45. PubMed ID: 30081071
[TBL] [Abstract][Full Text] [Related]
11. Reporting of statistically significant results at ClinicalTrials.gov for completed superiority randomized controlled trials.
Dechartres A; Bond EG; Scheer J; Riveros C; Atal I; Ravaud P
BMC Med; 2016 Nov; 14(1):192. PubMed ID: 27899150
[TBL] [Abstract][Full Text] [Related]
12. The fate of prospective spine studies registered on www.ClinicalTrials.gov.
Ohnmeiss DD
Spine J; 2015 Mar; 15(3):487-91. PubMed ID: 25315132
[TBL] [Abstract][Full Text] [Related]
13. Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications.
Shepshelovich D; Goldvaser H; Wang L; Abdul Razak AR; Bedard PL
Invest New Drugs; 2017 Dec; 35(6):827-833. PubMed ID: 28905282
[TBL] [Abstract][Full Text] [Related]
14. Serious Adverse Events Reporting in Phase III Randomized Clinical Trials of Colorectal Cancer Treatments: A Systematic Analysis.
Yao Y; Liu Z; Zhang H; Li J; Peng Z; Yu J; Cao B; Shen L
Front Pharmacol; 2021; 12():754858. PubMed ID: 34867369
[No Abstract] [Full Text] [Related]
15. Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: A meta-analysis.
de Vries YA; Roest AM; Beijers L; Turner EH; de Jonge P
Eur Neuropsychopharmacol; 2016 Nov; 26(11):1752-1759. PubMed ID: 27659240
[TBL] [Abstract][Full Text] [Related]
16. ClinicalTrials.gov and Drugs@FDA: A Comparison of Results Reporting for New Drug Approval Trials.
Schwartz LM; Woloshin S; Zheng E; Tse T; Zarin DA
Ann Intern Med; 2016 Sep; 165(6):421-30. PubMed ID: 27294570
[TBL] [Abstract][Full Text] [Related]
17. Comparison of reporting phase III randomized controlled trials of antibiotic treatment for common bacterial infections in ClinicalTrials.gov and matched publications.
Shepshelovich D; Yelin D; Gafter-Gvili A; Goldman S; Avni T; Yahav D
Clin Microbiol Infect; 2018 Nov; 24(11):1211.e9-1211.e14. PubMed ID: 29454846
[TBL] [Abstract][Full Text] [Related]
18. Statistical controversies in clinical research: comparison of primary outcomes in protocols, public clinical-trial registries and publications: the example of oncology trials.
Perlmutter AS; Tran VT; Dechartres A; Ravaud P
Ann Oncol; 2017 Apr; 28(4):688-695. PubMed ID: 28011448
[TBL] [Abstract][Full Text] [Related]
19. Harms Reporting in Randomized Controlled Trials of Interventions Aimed at Modifying Microbiota: A Systematic Review.
Bafeta A; Koh M; Riveros C; Ravaud P
Ann Intern Med; 2018 Aug; 169(4):240-247. PubMed ID: 30014150
[TBL] [Abstract][Full Text] [Related]
20. Haphazard reporting of deaths in clinical trials: a review of cases of ClinicalTrials.gov records and matched publications-a cross-sectional study.
Earley A; Lau J; Uhlig K
BMJ Open; 2013 Jan; 3(1):. PubMed ID: 23335556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
